Bank of New York Mellon Corp Sells 130,726 Shares of Novo Nordisk A/S $NVO

Bank of New York Mellon Corp cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 21.7% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 472,874 shares of the company’s stock after selling 130,726 shares during the quarter. Bank of New York Mellon Corp’s holdings in Novo Nordisk A/S were worth $17,378,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Quotient Wealth Partners LLC grew its position in Novo Nordisk A/S by 2.0% during the fourth quarter. Quotient Wealth Partners LLC now owns 9,091 shares of the company’s stock valued at $463,000 after buying an additional 177 shares during the period. Certuity LLC raised its position in Novo Nordisk A/S by 3.6% in the fourth quarter. Certuity LLC now owns 5,052 shares of the company’s stock worth $257,000 after acquiring an additional 177 shares during the period. Oakworth Capital Inc. boosted its stake in Novo Nordisk A/S by 41.6% in the fourth quarter. Oakworth Capital Inc. now owns 619 shares of the company’s stock valued at $31,000 after acquiring an additional 182 shares during the last quarter. True North Advisors LLC boosted its stake in Novo Nordisk A/S by 3.9% in the fourth quarter. True North Advisors LLC now owns 5,305 shares of the company’s stock valued at $270,000 after acquiring an additional 199 shares during the last quarter. Finally, Asio Capital LLC increased its stake in shares of Novo Nordisk A/S by 3.9% during the 4th quarter. Asio Capital LLC now owns 5,386 shares of the company’s stock worth $274,000 after purchasing an additional 200 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $51.56 on Thursday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.56 and a current ratio of 0.79. Novo Nordisk A/S has a fifty-two week low of $35.12 and a fifty-two week high of $64.16. The stock has a market cap of $230.22 billion, a PE ratio of 12.10, a price-to-earnings-growth ratio of 4.65 and a beta of 0.77. The stock has a fifty day moving average of $46.73 and a 200-day moving average of $45.54.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The business had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities research analysts anticipate that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on NVO shares. Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Nordea Equity Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Friday, June 19th. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, July 6th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th. Five equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk partnered with Crux to make Wegovy and other GLP-1 obesity treatments more accessible through U.S. employer health plans. Simpler benefit structures and more predictable pricing could broaden coverage and support demand. Novo Nordisk Teams Up With Crux To Expand Wegovy Access
• Positive Sentiment: The European Commission’s authorization of a once-daily oral Wegovy pill, combined with the U.S. access agreement, strengthens Novo Nordisk’s obesity-treatment portfolio. An oral option could improve patient convenience and expand the addressable market, although commercial uptake remains to be demonstrated. Novo Nordisk Is Up After EU Wegovy Pill Approval And US Access Deal
• Neutral Sentiment: Investors are watching upcoming second-quarter results for evidence that Ozempic and Wegovy sales, oral-product launches and label expansions can sustain growth despite intensifying competition. Strong results or guidance could support the shares, while signs of slowing momentum could weigh on them. How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q2 Results?
• Negative Sentiment: A U.S. judge allowed parts of a shareholder lawsuit alleging Novo Nordisk misled investors about a clinical trial for CagriSema to proceed. The case could create legal costs and reputational damage, while raising concerns about disclosures surrounding a key future growth product. Why Shareholders Are Suing Novo Nordisk Over CagriSema

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.